SCHEMBL24133302

SCHEMBL24133302

COCOc1ccc(C)cc1C(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
TRPA1 O75762 1/20 0.40
CHRM1 P11229 1/20 0.40
SLC6A2 P23975 1/20 0.40
ADRA1A P35348 1/20 0.40
HTR2B P41595 1/20 0.40
ACHE P22303 1/20 0.39
ALDH1A1 P00352 6/20 0.38
KDM4E B2RXH2 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HPGD P15428 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 2/20 0.36
CYP3A4 P08684 1/20 0.36
ADRB2 P07550 1/20 0.36
NPBWR1 P48145 1/20 0.36
MCHR1 Q99705 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18959733 0.84 ALDH1A1 (0.45) ALDH1A1KDM4ETDP1SMN1; SMN2HPGD
SCHEMBL9945918 0.83 L3MBTL1 (0.46) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL17034855 0.81 GAA (0.40) LMNAALDH1A1SMN1; SMN2HPGDMAPT
SCHEMBL282475 0.81 ALDH1A1 (0.47) LMNAALDH1A1KDM4ETDP1SMN1; SMN2
SCHEMBL29970124 0.81 GABRA1 (0.37) LMNAALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL19617651 0.81 GABRA1 (0.37) LMNAALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL27645331 0.81 GAA (0.45) LMNAALDH1A1KDM4ETDP1L3MBTL1
SCHEMBL22320321 0.80 PTGDR2 (0.40) KDM4EHPGDL3MBTL1MEN1KMT2A
SCHEMBL11890520 0.79 ACHE (0.52) ACHEALDH1A1KDM4ETDP1SMN1; SMN2
SCHEMBL30802160 0.79 ACHE (0.52) ACHEALDH1A1KDM4ETDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242473-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 US disclosed
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 US disclosed
EP-3936497-A1 PROCESS FOR THE PREPARATION OF DERIVATIVES OF SOBETIROME Oregon Health & Science University (US) 2022-01-12 EP disclosed
WO-2021257804-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-12-23 WO disclosed
WO-2021257834-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242473-A1 THYROMIMETICS TPO, THOP1, THRB LMNA 1686/4885TRPA1 3369/4885CHRM1 139/4885
US-20230242471-A1 THYROMIMETICS TPO, THOP1, THRB LMNA 1814/4885TRPA1 3317/4885CHRM1 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.